Daphna Laifenfeld, Claudia Albeldas, Talia Cohen Solal, Roger S McIntyre, Stephen Stahl
{"title":"走向精准精神病学:抑郁症治疗的创新与展望。","authors":"Daphna Laifenfeld, Claudia Albeldas, Talia Cohen Solal, Roger S McIntyre, Stephen Stahl","doi":"10.4088/PCC.25nr03970","DOIUrl":null,"url":null,"abstract":"<p><p><b>Importance:</b> Major depressive disorder is a heterogeneous disorder affecting over 280 million people globally. Despite multiple treatment options, individual response to drugs varies significantly, and most patients go through a trial-and-error approach, resulting in multiple drug iterations before alleviation of symptoms is achieved. Treatment optimization is further complicated by lack of full elucidation of the neurobiology of depression. The high prevalence of nonresponse, coupled with the detrimental effects of prolonged disease on patient welfare, economic burden, and increased likelihood of recurrence, substantiates the critical need for robust tools capable of precisely matching patients with their most effective and safe treatment options in a time-sensitive manner.</p><p><p><b>Observations:</b> Research into technologies that tailor treatments to individual patients based on their unique molecular and cellular characteristics has led to the development of precision medicine tools ranging from pharmacogenetics through peripheral biomarkers and neuroimaging to a platform that uses patient-derived neurons as a substrate for in vitro patient-specific functional readouts.</p><p><p><b>Conclusions and relevance:</b> Novel precision medicine tools in depression are being introduced that aim to identify the optimal treatment for each patient. Such tools have the potential to significantly improve depression management by guiding treatment selection for prescribers and people with lived experience.</p><p><p><i>Prim Care Companion CNS Disord 2025;27(5):25nr03970</i>.</p><p><p>\n <i>Author affiliations are listed at the end of this article.</i>\n </p>","PeriodicalId":22814,"journal":{"name":"The primary care companion for CNS disorders","volume":"27 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Toward Precision Psychiatry: Innovations and Prospects in Treating Depression.\",\"authors\":\"Daphna Laifenfeld, Claudia Albeldas, Talia Cohen Solal, Roger S McIntyre, Stephen Stahl\",\"doi\":\"10.4088/PCC.25nr03970\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Importance:</b> Major depressive disorder is a heterogeneous disorder affecting over 280 million people globally. Despite multiple treatment options, individual response to drugs varies significantly, and most patients go through a trial-and-error approach, resulting in multiple drug iterations before alleviation of symptoms is achieved. Treatment optimization is further complicated by lack of full elucidation of the neurobiology of depression. The high prevalence of nonresponse, coupled with the detrimental effects of prolonged disease on patient welfare, economic burden, and increased likelihood of recurrence, substantiates the critical need for robust tools capable of precisely matching patients with their most effective and safe treatment options in a time-sensitive manner.</p><p><p><b>Observations:</b> Research into technologies that tailor treatments to individual patients based on their unique molecular and cellular characteristics has led to the development of precision medicine tools ranging from pharmacogenetics through peripheral biomarkers and neuroimaging to a platform that uses patient-derived neurons as a substrate for in vitro patient-specific functional readouts.</p><p><p><b>Conclusions and relevance:</b> Novel precision medicine tools in depression are being introduced that aim to identify the optimal treatment for each patient. Such tools have the potential to significantly improve depression management by guiding treatment selection for prescribers and people with lived experience.</p><p><p><i>Prim Care Companion CNS Disord 2025;27(5):25nr03970</i>.</p><p><p>\\n <i>Author affiliations are listed at the end of this article.</i>\\n </p>\",\"PeriodicalId\":22814,\"journal\":{\"name\":\"The primary care companion for CNS disorders\",\"volume\":\"27 5\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The primary care companion for CNS disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4088/PCC.25nr03970\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The primary care companion for CNS disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4088/PCC.25nr03970","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Toward Precision Psychiatry: Innovations and Prospects in Treating Depression.
Importance: Major depressive disorder is a heterogeneous disorder affecting over 280 million people globally. Despite multiple treatment options, individual response to drugs varies significantly, and most patients go through a trial-and-error approach, resulting in multiple drug iterations before alleviation of symptoms is achieved. Treatment optimization is further complicated by lack of full elucidation of the neurobiology of depression. The high prevalence of nonresponse, coupled with the detrimental effects of prolonged disease on patient welfare, economic burden, and increased likelihood of recurrence, substantiates the critical need for robust tools capable of precisely matching patients with their most effective and safe treatment options in a time-sensitive manner.
Observations: Research into technologies that tailor treatments to individual patients based on their unique molecular and cellular characteristics has led to the development of precision medicine tools ranging from pharmacogenetics through peripheral biomarkers and neuroimaging to a platform that uses patient-derived neurons as a substrate for in vitro patient-specific functional readouts.
Conclusions and relevance: Novel precision medicine tools in depression are being introduced that aim to identify the optimal treatment for each patient. Such tools have the potential to significantly improve depression management by guiding treatment selection for prescribers and people with lived experience.
Prim Care Companion CNS Disord 2025;27(5):25nr03970.
Author affiliations are listed at the end of this article.
期刊介绍:
Founded in 1998, The Primary Care Companion for CNS Disorders (ISSN 2155-7780), formerly The Primary Care Companion to The Journal of Clinical Psychiatry, is an international, peer-reviewed, online-only journal, and its articles are indexed by the National Library of Medicine. PCC seeks to advance the clinical expertise of primary care physicians and other health care professionals who treat patients with mental and neurologic illnesses. PCC publishes research from disciplines such as medicine, nursing, pharmacy, and psychology, especially as it pertains to integrated delivery systems and interdisciplinary collaboration. PCC focuses on providing information of direct clinical utility and giving a voice to clinician researchers. Practice-based research from individuals and groups with clinical expertise is particularly welcome. Pertinent manuscript types include: -Original research -Systematic reviews -Meta-analyses -Case reports and series -Commenting letters to the editor Articles published in PCC typically cover attention-deficit/hyperactivity disorder, depression, bipolar disorder, anxiety, addiction, sleep disorders, pain, Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.